title: Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE.
authors.affiliation: Centre of Cardiovascular Research & Education in Therapeutics, Monash University, Melbourne, Australia.
authors.forename: Henry
authors.initials: H
authors.lastname: Krum
authors.forename: Barrie
authors.initials: B
authors.lastname: Massie
authors.forename: William T
authors.initials: WT
authors.lastname: Abraham
authors.forename: Kenneth
authors.initials: K
authors.lastname: Dickstein
authors.forename: Lars
authors.initials: L
authors.lastname: Kober
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
mesh_terms: D000577:Amides / Q000627:therapeutic use*; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000150:complications; D004359:Drug Therapy, Combination; D005650:Fumarates / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D013318:Stroke Volume; D018487:Ventricular Dysfunction, Left; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D005650:Fumarates; D000092502:Renin Inhibitors; C446481:aliskiren